Isomorphic Labs Inc. fundraising

Isomorphic Labs Inc., a subsidiary of Alphabet Inc., is reportedly in discussions to secure a new funding round aimed at advancing its AI-driven drug development initiatives. Sources indicate the infusion could surpass $2 billion, with investment firm Thrive Capital—an existing stakeholder and backer of OpenAI Group PBC—anticipated to lead the round. Alphabet itself is expected to participate in this financing effort.

Formed in 2021 by spinning out from Google DeepMind, Isomorphic Labs is steered by Demis Hassabis, a DeepMind co-founder and a 2024 Nobel Prize co-recipient for breakthroughs in protein structure prediction with AlphaFold 2. This model drastically reduced the time required to predict protein structures, a foundational task in drug development. In the following year, Isomorphic Labs and DeepMind introduced AlphaFold 3, boasting over a 50% improvement in accuracy for select research activities, particularly those involving small molecules.

At the core of Isomorphic Labs' offerings lies the Isomorphic Labs Drug Design Engine (IsoDDE), an AI system intended to automate complex drug development processes. IsoDDE is positioned as more effective than its predecessor, AlphaFold 3, particularly in identifying binding pockets on proteins—key access points for drug delivery into cells. During testing on the Runs N’ Poses benchmark, IsoDDE reportedly achieved scores more than double those of AlphaFold 3 on challenging tasks. This capability, alongside its reduced data requirements, enhances the efficiency of drug discovery projects.

The potential new funding is earmarked for further development of IsoDDE and expanding the company’s global footprint. Isomorphic Labs is focused on facilitating the speed and accuracy of identifying therapeutic compounds, which attach to proteins at binding sites. By increasing predictive accuracy, IsoDDE aims to streamline the process of identifying effective drug candidates, a critical step in the pharmaceutical development cycle.

This funding effort underlines the competitive push within the medical research AI sector to innovate drug discovery methods amidst growing interest in AI's role in biosciences. With pharmaceutical firms seeking to cut down time and cost in bringing new drugs to market, AI models like IsoDDE represent promising tools for achieving these objectives. As Isomorphic Labs looks to deploy the new capital, industry observers will watch how advancements in AI-driven drug design impact traditional pharmaceutical R&D practices and timelines.